Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Current Deferred Revenue: 2013-2023

Historic Current Deferred Revenue for Theravance Biopharma (TBPH) over the last 10 years, with Sep 2023 value amounting to $24,000.

  • Theravance Biopharma's Current Deferred Revenue changed negligibly% to $24,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $24,000, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $24,000 for FY2022, which is 75.51% down from last year.
  • Per Theravance Biopharma's latest filing, its Current Deferred Revenue stood at $24,000 for Q3 2023, which was down 0.00% from $24,000 recorded in Q2 2023.
  • Theravance Biopharma's 5-year Current Deferred Revenue high stood at $43.3 million for Q2 2019, and its period low was $24,000 during Q2 2022.
  • Its 3-year average for Current Deferred Revenue is $1.5 million, with a median of $24,000 in 2023.
  • Data for Theravance Biopharma's Current Deferred Revenue shows a maximum YoY crashed of 99.58% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Theravance Biopharma's Current Deferred Revenue stood at $31.6 million in 2019, then crashed by 63.51% to $11.5 million in 2020, then slumped by 99.15% to $98,000 in 2021, then tumbled by 75.51% to $24,000 in 2022, then remained steady at $24,000 in 2023.
  • Its Current Deferred Revenue stands at $24,000 for Q3 2023, versus $24,000 for Q2 2023 and $24,000 for Q1 2023.